Stock Traders Buy High Volume of Call Options on Aldeyra Therapeutics (NASDAQ:ALDX)

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) saw some unusual options trading on Tuesday. Stock traders bought 12,807 call options on the company. This represents an increase of approximately 1,592% compared to the typical volume of 757 call options.

Aldeyra Therapeutics Stock Down 1.1%

Shares of ALDX opened at $5.25 on Thursday. The stock has a market cap of $315.84 million, a P/E ratio of -7.19 and a beta of 0.83. The business’s 50 day moving average price is $5.09 and its 200-day moving average price is $4.86. Aldeyra Therapeutics has a 52 week low of $1.14 and a 52 week high of $7.20.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings data on Wednesday, November 5th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.04. On average, equities analysts anticipate that Aldeyra Therapeutics will post -0.92 EPS for the current year.

Institutional Trading of Aldeyra Therapeutics

Institutional investors have recently bought and sold shares of the company. Public Employees Retirement System of Ohio bought a new stake in shares of Aldeyra Therapeutics in the 2nd quarter worth $25,000. Inspirion Wealth Advisors LLC purchased a new stake in shares of Aldeyra Therapeutics during the second quarter valued at $38,000. CIBC Private Wealth Group LLC bought a new stake in Aldeyra Therapeutics in the 3rd quarter worth about $55,000. BNP Paribas Financial Markets increased its holdings in Aldeyra Therapeutics by 36.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 10,610 shares of the biotechnology company’s stock worth $55,000 after buying an additional 2,859 shares in the last quarter. Finally, King Wealth Management Group purchased a new position in Aldeyra Therapeutics in the 2nd quarter worth about $46,000. 59.71% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ALDX has been the topic of several recent research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aldeyra Therapeutics in a research note on Wednesday, October 8th. BTIG Research reissued a “buy” rating and set a $9.00 price objective on shares of Aldeyra Therapeutics in a research report on Monday, November 10th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $9.50.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.